BiomX Advances Phage-Based Therapy for Diabetic Foot Infections
BiomX's Innovative Approach to Diabetic Foot Infections BiomX Inc. (NYSE: PHGE), a pioneering clinical-stage company specializing in natural and engineered phage therapies, has announced exciting developments regarding its novel treatment for diabetic foot infections (DFI). Following supportive feedback from the U.S. Food and Drug Administration (FDA), BiomX is gearing up...
Continue Reading